Addex Therapeutics (ADXN) Current Assets (2018 - 2026)
Addex Therapeutics (ADXN) posted Current Assets of $1.5 million for Q1 2026, down 27.73% sequentially from $2.1 million in Q4 2025, and down 57.28% YoY from $3.6 million in Q1 2025.
Addex Therapeutics (ADXN) Current Assets (2018 - 2026) Analysis & Trends
Addex Therapeutics has reported Current Assets for 9 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Current Assets fell 57.28% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 57.28% YoY) and the FY2025 annual result came in at $2.0 million, down 49.66% from the prior year.
- Current Assets fell to $1.5 million in Q1 2026 per ADXN's latest filing, from $2.1 million in the prior quarter.
- Over five years, Current Assets peaked at $18.6 million in Q1 2022 and troughed at $1.5 million in Q1 2026.
- A 5-year average of $6.5 million and a median of $4.8 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2025: Current Assets slumped 65.85% in 2022, then slipped 5.85% in 2025.
- Over 5 years, Current Assets stood at $8.1 million in 2022, then slumped by 41.26% to $4.8 million in 2023, then slipped by 15.32% to $4.0 million in 2024, then slumped by 48.0% to $2.1 million in 2025, then declined by 27.73% to $1.5 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $1.5 million, $2.1 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | 1.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.52 Mn |
| Dec 31, 2025 | 2.10 Mn |
| Sep 30, 2025 | 2.96 Mn |
| Jun 30, 2025 | 3.21 Mn |
| Mar 31, 2025 | 3.56 Mn |
| Dec 31, 2024 | 4.04 Mn |
| Sep 30, 2024 | 4.70 Mn |
| Jun 30, 2024 | 5.19 Mn |
| Mar 31, 2024 | 3.78 Mn |
| Dec 31, 2023 | 4.77 Mn |
| Sep 30, 2023 | 6.50 Mn |
| Jun 30, 2023 | 9.67 Mn |
| Mar 31, 2023 | 7.48 Mn |
| Dec 31, 2022 | 8.13 Mn |
| Sep 30, 2022 | 12.12 Mn |
| Jun 30, 2022 | 11.37 Mn |
| Mar 31, 2022 | 18.58 Mn |
| Dec 31, 2021 | 23.80 Mn |
| Sep 30, 2021 | 18.99 Mn |
| Jun 30, 2021 | 23.03 Mn |